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The inhibition of carbohydrate-hydrolysing enzymes in human digestive organs is crucial in controlling blood sugar 
levels, which is important in treating type 2 diabetes. In the current study, Pahangensin A (1), a bis-labdanic 
diterpene previously characterized in the rhizomes of Alpinia pahangensis Ridley, was identified as an active dual 
inhibitor for α-amylase (IC50 = 114.80 μM) and α-glucosidase (IC50 = 153.87 μM). This is the first report on the 
dual α-amylase and α-glucosidase inhibitory activities of a bis-labdanic diterpene. The Lineweaver-Burk plots of 
compound 1 indicate that it is a mixed-type inhibitor with regard to both enzymes. Based on molecular docking 
studies, compound 1 docked in a non-active site of both enzymes. The dual inhibitory activity of compound 1 
makes it a suitable natural alternative in the treatment of type 2 diabetes.  
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Introduction 
 
Diabetes mellitus is a metabolic disorder characterized by high plasma glucose levels, classified as either type 1 
or 2. Type 1, or insulin-dependent diabetes, is due to failure of the pancreas to secrete insulin, while type 2, or 
non-insulin-dependent diabetes, is the result of insufficient insulin production. Type 2 diabetes receives more 
attention than type 1 diabetes because it is considered to be preventable. The former is caused by an imbalance 
between blood sugar absorption and insulin secretion. Post-prandial hyperglycaemia plays an important role in 
the development of type 2 diabetes. Controlling plasma glucose levels is essential for delaying or preventing type 
2 diabetes.[1] 
 
α-Amylase and α-glucosidase inhibitors belong to a class of anti-diabetic drugs that control the sudden rise in 
blood sugar levels after meals. α-Amylase is in a class of enzymes that hydrolyse polysaccharides to 
oligosaccharides, while α-glucosidase catalyses the final step in carbohydrate hydrolysis to release the 
absorbable monosaccharides.[2] Both of these carbohydrate-hydrolysing enzymes are secreted in the small 
intestine, while α-amylase is also found in the saliva.[1] Thus, the inhibition of these enzymes plays an important 
role in the management of diabetic complications, particularly type 2 diabetes.[2-3] Antidiabetic drugs such as 
acarbose, miglitol and voglibose act by inhibiting the activities of α-amylase and α-glucosidase. Although these 
drugs are effective, continuous use may lead to undesirable side effects, which include liver toxicity and adverse 
gastrointestinal symptoms.[4] Hence, discovering new potential inhibitors from plants may offer reduced side 
effects during long-term use.  
 
A large number of traditional medicinal plants and plant-derived constituents, such as terpenes, alkaloids, 
curcuminoids, anthocyanins, flavonoids, quinones, phenols, phenylpropanoids, acylphenols and dimeric 
acylphenols, are known to exhibit α-amylase and α-glucosidase inhibitory activities.[2] [5-8] However, to date, bis-
labdanic diterpenes have never been investigated for their potential to inhibit these enzymes. Therefore, herein, 
we report the dual inhibiting potentials of Pahangensin A (1) (Figure 1), a bis-labdanic diterpene previously 
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isolated and characterized from the rhizomes of Alpinia pahangensis Ridley, against α-amylase and α-
glucosidase.[9] Kinetic studies were subsequently carried out on compound 1 to determine its mode of inhibition 
against each enzyme. Additionally, molecular docking was performed to provide insights into the binding 
interactions between compound 1 and the enzymes.  
 
 
 
 
Figure 1: Structure of compound 1 
 
 
Results and Discussion 
 
The IC50 values of compound 1 and the positive control, acarbose are given in Table 1. The inhibition potential of 
compound 1 against the carbohydrate-hydrolysing enzymes was higher compared to acarbose, thus making 
compound 1 a more effective inhibitor than the positive control.  
 
Table 1: Carbohydrate hydrolyzing enzymes inhibition of compound 1 and acarbose.  
 
Compounds IC50 (µM)a 
α-Amylase α-Glucosidase 
1 114.80 ± 8.49 153.87 ± 9.28 
Acarbose  280.47 ± 10.19 1449. 67 ± 46.52 
a Data presented as Mean ± SD (n = 3). 
 
As illustrated by Lineweaver-Burk plot analyses (Figure 2), compound 1 displayed mixed-mode inhibition against 
α-amylase and α-glucosidase, as indicated by the intersect in the second quadrant of each respective plot. This 
finding suggested that compound 1 will be able to bind to the free enzymes and enzyme-substrate complexes.[5] 
[10-11]  
 
 
 
Figure 2: Lineweaver-Burk plots for (A and B) α-glucosidase and (C and D) α-amylase in the presence of 
acarbose and compound 1, respectively. Mode of inhibition was determined by analysing the Lineweaver–Burk 
plots, which was obtained from the Michaelis–Menten kinetics (Supp 1). 
  
3 
 
The free enzyme inhibition of compound 1, which was smaller than its enzyme-substrate complex inhibition 
constants (Table 2), enabled us to postulate that compound 1 has a higher affinity towards the free enzymes 
rather than the enzyme-substrate complexes, which is typical for mixed-mode inhibitors.[11] In the current study, 
acarbose was identified as a competitive inhibitor of α-glucosidase and a mixed-mode inhibitor of α-amylase, 
which is consistent with previous reports.[5] [12] 
 
Table 2: Mode of inhibition and inhibitory constants of compound 1 and acarbose against α-amylase and α-
glucosidase.  
 
Compound α-Amylase α-Glucosidase 
 
Mode of 
Inhibition 
Ki1 (µM) Ki2 (µM) Mode of Inhibition *Ki1 (µM) *Ki2 (µM) 
1 Mixed-mode 47.66 ± 8.24 
68.78 ± 
11.75 
Mixed-mode 
124.77 ± 
12.16 
140.93 ± 
20.49 
Acarbose Mixed-mode 26.04 ± 2.67 
61.18 ± 
10.45 
Competitive 
568.47 ± 
107.04 
- 
*Ki1 and Ki2 indicate the affinity of the inhibitors to the free enzyme and the enzyme-substrate complex, 
respectively. 
 
The crystal structures of α-amylase (PDB ID: 1OSE)[13] and α-glucosidase (PDB ID: 3A4A)[14] have identified 
active sites and based on the molecular docking studies (Figures 3 and 4), acarbose and compound 1 showed 
favourable interactions with residues of the enzyme’s binding pockets. Acarbose docked in the active site of α-
glucosidase, but only interacted with a non-active site in α-amylase. This finding in turn provided supportive data 
of our experimental results that acarbose inhibited α-glucosidase and α-amylase in competitive and mixed-mode 
manners, respectively. As shown in Figure 3, the docked conformation of acarbose revealed the formation of two 
hydrogen bonds with the important active site residues of -glucosidase, GLU277 and ASP352. On the other 
hand, compound 1 docked into the non-active site of both α-glucosidase and α-amylase (Figure 4), which is in 
agreement with our experimental data suggested that compound 1 was a mixed-mode inhibitor. In contrast to 
acarbose, compound 1 has only one hydrogen bond with α-amylase (GLY306). The majority of the interactions 
involved alkyl-alkyl and pi-alkyl interactions with ILE235, LYS 200, HIS201, ALA307, ILE148 and VAL163. Similar 
types of interactions were also observed with α-glucosidase, with only one hydrogen bond to ARG176 and the 
majority being alkyl-alkyl and pi-alkyl interactions (PRO149, PHE166, TRP238, PHE173, PRO151 and LYS148). 
The results also revealed better binding energies for compound 1 (-9.8 and -11.0 kcal/mol) compared to acarbose 
(-8.8 and -8.4 kcal/mol) for α-amylase and α-glucosidase, respectively. 
 
 
Figure 3: The docked acarbose in (A, C and E) α-amylase (PDB: 1OSE)[13] and (B, D and F) α-glucosidase 
(PDB: 3A4A)[14] is shown in 3-D and 2-D. The results show acarbose is docked into the α-glucosidase’s active 
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site with 2 important active site residues, Glu277 and Asp352 via hydrogen bonding. However, acarbose only 
docked into the non-active site of the α-amylase enzyme.  
 
 
Figure 4: The docked compound 1 in (A, C and E) α-amylase (PDB: 1OSE)[13]  and (B, D and F) α-glucosidase 
(PDB: 3A4A)[14]  is shown in 3-D and 2-D. The results show compound 1 is docked into the non-active site of the 
α-amylase and α-glucosidase enzymes.  
 
 
Conclusions 
 
Diabetes mellitus is a metabolic disorder that leads to comorbidities such as neuropathy, nephropathy, 
retinopathy and cardiovascular diseases.[15] Control of postprandial glucose levels is one way to reduce 
postprandial spikes.[16] Hence, controlling the activities of α-amylase and α-glucosidase seems to be useful in 
preventing a postprandial spike.[16] In the present study, compound 1 exhibited stronger inhibitory effects towards 
α-amylase and α-glucosidase in comparison to acarbose. Molecular docking revealed that the interactions of 
compound 1 with both enzymes involved mainly hydrophobic interactions (alkyl-alkyl and pi-alkyl). The weak 
inhibition of α-glucosidase by acarbose is known to cause adverse effects, such as flatulence from the breakdown 
of undigested carbohydrates by intestinal bacteria.[15] Therefore, a compound with dual inhibition may elicit its 
pharmacological effects while minimizing its side effects.[18] The results presented here indicate that compound 1 
is a promising α-amylase and α-glucosidase inhibitor for further development as a potential alternative to 
acarbose. Since, the enzymes used are non-human types, compound 1 can be a lead compound for medicinal 
chemists to further develop analogues, which may potentially inhibit human α-amylase and α-glucosidase. 
 
 
Experimental Section 
 
Chemicals and reagents  
 
Analytical and preparative TLC were carried out on Merck 60 F254 silica gel plates (absorbent thickness: 0.25 and 
0.50 mm). Column chromatography was performed using silica gel (Merck 230-400 mesh, ASTM). The IR 
spectrum was recorded using a Perkin-Elmer Spectrum 400 FT-IR Spectrometer. NMR spectra were recorded in 
CDCl3 (Merck, Germany) with tetramethylsilane as an internal standard using a JEOL ECA 400 MHz NMR 
spectrometer. The LCMS-IT-TOF spectrum was recorded on a UFLC Shimadzu Liquid Chromatograph with an 
SPD-M20A diode array detector coupled to an IT-TOF mass spectrometer. The UV spectrum was recorded using 
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a Shimadzu 1650 PC UV-Vis Spectrophotometer. All solvents were of analytical grade and were distilled prior to 
use.[9] 
 
The α-glucosidase enzyme (EC 3.2.1.20) was obtained from the yeast Saccharomyces cerevisiae, while the α-
amylase enzyme (EC 3.2.1.1) was obtained from the porcine pancreas. All reagents, chemicals and enzymes 
were purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO, USA). 
 
Plant material  
 
A. pahangensis was collected from Pahang in 2011. The plant was identified by one of our authors, Professor 
Halijah Ibrahim, and a voucher specimen (KU001) was deposited with the University of Malaya herbarium.[9] 
 
Extraction, isolation and characterization of compound 1 
 
Dried powdered rhizomes (1.0 kg) of A. pahangensis were extracted with CH2Cl2 (5.0 L, 2×) followed by MeOH 
(5.0 L, 2×) at room temperature, giving 15.55 g and 19.04 g of extracts, respectively. The CH2Cl2 extract was 
fractionated over a silica gel column eluting with mixtures of hexane:CH2Cl2 in proportions of 50:50 (v/v, 450 mL), 
25:75 (v/v, 550 mL), and 0:100 (v/v, 1950 mL), followed by mixtures of CH2Cl2:MeOH in proportions of 95:5 (v/v, 
400 mL) and 85:15 (v/v, 400 mL) to yield 10 main fractions (AP1-AP10). Repeated preparative TLC of fraction 
AP 4 (1.00 g; eluted with hexane:CH2Cl2 [25:75 v/v]) with hexane:EtOAc (95:5 v/v) led to the isolation of 1 (20.0 
mg).[9] The purity of Pahangensin A is 98.2%, determined from the peak area of the LCMS-DAD-IT-TOF analysis 
(Supp 2).  
 
Pahangensin A (= bis-labda-8(17),11,13-trien-16,15-olide; 1): Yellow oil, UV λmax (MeOH) nm (log ε): 205 
(7.58), and 281 (11.80); IR λmax (NaCl) cm-1: 3069, 2928, 2863, 2852, 1738, 1646, 1459, 1367, 889; LCMS-IT-
TOF m/z : 599.4071 [M + H]+ (calcd.for C40H55O4 599.4095); 1H NMR (CDCl3, 400 MHz):  δ 0.84 (3H, s, H-20/H-
20’), δ 0.85 (3H, s, H-19/H-19’), δ 0.90 (3H, s, H-18/H-18’), δ 1.05 (1H, m, H-1α/H-1’α), δ 1.13 (1H, dd, J = 12.4, 
2.3 Hz, H-5α/H-5’α), δ 1.20 (1H, m, H-3α/H-3’α), δ 1.37-1.45 (4H, m, H-1β/H-1’β, H-2α/H-2’α, H-3β/H-3’β, H-6α/H-
6’α), δ 1.52 (1H, m, H-2β/H-2’β), δ 1.73 (1H, m, H-6β/H-6’β), δ 2.10 (1H, m, H-7α/H-7’α), δ 2.44 (1H, m, H-7β/H-
7’β), δ 2.48 (1H, brd, J = 11.0 Hz, H-9α/H-9’α), δ 4.42 (1H, d, J = 1.2 Hz, H-17a/H-17’a), δ 4.78 (1H, d, J = 1.2 
Hz, H-17b/H-17’b), δ 4.88 (2H, brs, H-16/H-16’), δ 6.00 (1H, dd, J = 16.5, 10.0 Hz, H-11/H-11’), δ 6.36 (1H, d, J 
= 16.5 Hz, H-12/H-12’);  13C NMR (CDCl3, 400 MHz): δ 15.3 (C-20/C-20’), δ 19.3 (C-2/C-2’), δ 22.2 (C-19/C-19’), 
δ 23.5 (C-6/C-6’), δ 33.8 (C-4/C-4’, C-18/C-18’), δ 36.9 (C-7/C-7’), δ 39.6 (C-10/C-10’), δ 41.2 (C-1/C-1’), δ 42.4 
(C-3/C-3’), δ 54.8 (C-5/C-5’), δ 62.2 (C-9/C-9’), δ 68.2 (C-16/C-16’), δ 108.5 (C-17/C-17’), δ 120.9 (C-12/C-12’), 
δ 127.5 (C-13/C-13’), δ 135.5 (C-11/C-11’), δ 135.7 (C-14/C-14’), δ 149.6 (C-8/C-8’), δ 171.3 (C-15/C-15’). [9] 
 
α-Glucosidase inhibitory assay 
 
Compound 1 was initially dissolved in dimethyl sulfoxide (DMSO) and further diluted with the respective assay 
buffers to yield a final concentration of 15% DMSO in buffer. Acarbose was directly dissolved in the respective 
assay buffers. Negative controls with 15% DMSO in the respective assay buffers were included to account for 
the effect of the solvent. A total volume of 40 µL of compound 1 at different concentrations (0.02 – 2.5 mM) was 
pre-incubated with 80 µL of potassium phosphate buffer (pH 6.8) containing 67 mM potassium phosphate and 
2.0 units/mL α-glucosidase in a 96-well plate for 10 minutes at 25 °C. Subsequently, 40 µL of 5 mM p-nitrophenyl-
α-D-glucopyranoside solution (p-NPG) in potassium phosphate buffer was introduced and incubated for another 
10 minutes. After incubation, 60 µL of 100 mM sodium carbonate was added to terminate the reaction, and the 
absorbance was measured at a wavelength of 415 nm using a microplate reader (Infinite 200, Tecan). Acarbose 
was utilized as a positive control. The concentration of compound 1 resulting in 50 % inhibition of the α-
glucosidase activity (IC50) was determined using the GraphPad Prism 5 statistical package (GraphPad Software, 
USA). All data are expressed as the mean ± standard deviation of triplicate determinations.[5] [19] 
 
α-Amylase inhibitory assay  
 
Porcine α-amylase (1.0 unit/mL) in a volume of 100 µL was pre-incubated with 10 µL of compound 1 at different 
concentrations (0.02 – 2.5 mM) for 10 minutes at 25 °C. Next, 100 µL of 0.5 % (w/v) starch solution containing 
0.5 % (w/v) potato starch in 20 mM sodium phosphate buffer (pH 6.9) with 6.7 mM sodium chloride was added to 
the solution and incubated for 8 minutes at 25 °C. Then, 100 µL of DNS colour agent solution containing 96 mM 
3,5-dinitrosalicylic acid solution and 5.31 M sodium potassium tartrate in 2 M sodium hydroxide was added into 
the solution and incubated again for 15 minutes at 85 °C. After incubation, the absorbance was measured at a 
wavelength of 540 nm using a microplate reader (Infinite 200, Tecan). The experiment was also carried out using 
the positive control, acarbose. Similarly, the concentration of compound 1 resulting in 50 % inhibition of the α-
amylase activity (IC50) was determined using the GraphPad Prism 5 statistical package (GraphPad Software, 
USA). All data are expressed as the mean ± standard deviation of triplicate determinations.[20] 
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Mode of α-glucosidase and α-amylase inhibition  
 
The inhibition modes of the compound 1 and acarbose samples against α-glucosidase and α-amylase were 
measured at different concentrations of their respective substrates (p-NPG or potato starch) in the presence or 
absence of samples at various concentrations. The mode of inhibition was obtained by Lineweaver-Burk plot 
analysis and calculated using Michaelis-Menten kinetics. A Dixon plot and the Y-intercept of the Lineweaver-Burk 
plot versus [inhibitor] were used to determine the inhibition constants (Ki). All data are expressed as the mean ± 
standard deviation of triplicate determinations.[5] [19] [21] The pathlength of the microplate reader (Infinite 200, 
Tecan) is 0.511 cm and extinction coefficient of compound 1 is 2.74 L mol-1 cm-1. 
 
Molecular docking  
 
Molecular docking was performed to investigate the binding mode between the samples (compound 1 and 
acarbose) and the enzymes (α-amylase and α-glucosidase) using Autodock Vina 1.1.2. The 3-D structures of 
compound 1 and acarbose were drawn and energy minimized using ChemBio3D Ultra 12.0. The crystal structures 
of α-amylase (PDB ID: 1OSE)[13]  and α-glucosidase (PDB ID: 3A4A)[14]  were prepared using AutoDockTools 
1.5.6 to remove water molecules and ligands (acarbose, α-D-glucose and β-D-glucose) and to add missing 
hydrogens. Although the active sites are identified in the crystal structures, the enzymes were enclosed in a grid 
box with 1.00 Å spacing, and the search exhaustiveness value was set to 100 to perform blind docking 
encompassing the whole enzyme structure. The top best-scoring pose from the AutoDock Vina results was 
analysed using Discovery Studio visualizer 4.5.[22]  
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